

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-31. (Canceled)

Claim 32. (Currently Amended) A method of inhibiting the IL-5, IL-3 or GM-CSF mediated proliferation of a chronic myelomonocytic cell leukaemia cell ~~proliferation~~ by contacting ~~the leukaemia~~ said cell ~~cells~~ with a BION-1 monoclonal antibody or fragments thereof capable of inhibiting the binding of cytokines IL-3, GM-CSF or IL-5 to the common receptor βc , wherein the monoclonal antibody or fragments thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the βc subunit, wherein said contacting results in inhibition of IL-5, IL-3 or GM-CSF mediated proliferation of said cell.

Claim 33. (Cancelled)

Claim 34. (Currently Amended) A method of inhibiting the IL-5, IL-3 or GM-CSF mediated eosinophil activation, eosinophil production or eosinophil survival, by contacting an eosinophil ~~the eosinophils~~ with a BION-1 monoclonal antibody or fragments thereof capable of inhibiting the binding of cytokines IL-3, GM-CSF or IL-5 to the common receptor βc , wherein the monoclonal antibody or fragments thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the βc subunit, wherein said contacting results in inhibition of IL-5, IL-3 or GM-CSF mediated activation, production or survival of said eosinophil.

Claim 35-43. (Cancelled)